Ardelyx, Inc. (ARDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.80+0.80%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Ardelyx aims to grow XPHOZAH revenue to about $115 million in 2026. The company expects total revenue near $270 million in 2025. Recent earnings beats show improving execution. New funding supports ongoing operations.
Ardelyx is still loss-making with negative free cash flow. Revenue growth may slow below targets. The recent 26% share price drop signals investor concerns. Debt raises add financial risk.
The market expects about 45% revenue growth next year. Our fair value near $21 implies these growth hopes. The recent selloff suggests some skepticism about execution and profitability.
Breaks if: New large debt or equity raises that dilute shareholders or increase leverage materially
Breaks if: EPS remains negative or below $0.50 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but has stable management and is focused on growing its revenue from key products.
The market seems to have priced in a low level of expectations, as indicated by a gap of -1.12. ARDX is considered cheap compared to its peers, but this valuation comes with a high level of risk.
Management is on track to meet revenue growth targets for its key products, IBSRELA and XPHOZAH. However, the company has a high probability of missing earnings expectations, which adds to the uncertainty.
The long-term thesis hinges on ARDX's ability to improve financial performance and manage risks related to economic conditions. Positive developments in the broader healthcare sector and successful trial outcomes could also play a crucial role.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own ARDX has diminished due to recent performance. The company's standing fell from the 62nd to the 49th percentile of its sector. Additionally, ARDX reported a significant earnings miss in its latest release.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: total revenue falls below $270 million in FY25
Breaks if: XPHOZAH revenue falls below $110 million in FY26
Over the next 1 to 3 years, ARDX's performance will depend on its execution and external market factors. Not investment advice.